Bio-Techne (TECH) Q4 CY2024 Highlights:
Revenue: $297 million vs analyst estimates of $285.1 million (9% year-on-year growth, 4.2% beat)
Adjusted EPS: $0.42 vs analyst estimates of $0.38 (9.3% beat)
Adjusted EBITDA: $96.11 million vs analyst estimates of $87.93 million (32.4% margin, 9.3% beat)
Operating Margin: 16%, up from 13.9% in the same quarter last year
Free Cash Flow Margin: 26.1%, up from 25% in the same quarter last year
Organic Revenue rose 9% year on year (-1.9% in the same quarter last year)
Market Capitalization: $11.53 billion
"The Bio-Techne team once again executed at a high level and delivered strong second quarter results," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne.
https://finance.yahoo.com/news/bio-techne-nasdaq-tech-surprises-114147351.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.